image credit- freepik
China-based Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., for the development, registration and commercialisation of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China.
Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.
This collaboration strengthens the company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.
Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD).
As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.
As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.
From a strategic perspective, this collaboration represents another important step in Everest Medicines’ ongoing efforts to deepen its presence across the Asia-Pacific region.
